This study is a single center trial to assess the safety and initial efficacy of intra-articular administration of Allocetra to patients with Temporomandibular Joint Osteoarthritis (TMJ-OA)

开始日期2024-12-15

申办/合作机构

Sheba Medical Center

[+1]

NCT06522035

/ Terminated临床1期

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

开始日期2024-08-01

申办/合作机构

Enlivex Ltd.

NCT06459063

/ Active, not recruiting临床1/2期IIT

A Placebo-controlled Study of Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint

This study is a single center trial to assess the safety and efficacy of intra-articular administration of Allocetra to patients with 1st CMC thumb joint osteoarthritis (OA).

开始日期2024-06-10

申办/合作机构-

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的文献（医药）

2024-08-19·MILITARY MEDICINE

Apoptotic Cell–Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock

Article

作者: Lutsker, Maya ; Kolben, Yotam ; Mevorach, Dror ; Wagnert-Avraham, Linn ; Aliev, Emil ; Kenig, Ariel ; Kessler, Asa ; Nachman, Dean

ABSTRACT:

Introduction:

Many trauma patients die from hemorrhagic shock in the military and civilian settings. Although two-thirds of hemorrhagic shock victims die of reasons other than exsanguination, such as the consequent cytokine storm, anti-inflammatory therapies failed to be utilized. Apoptotic cell–based treatments enhance innate ability to exert systemic immunomodulation as demonstrated in several clinical applications and hence might present a novel approach in hemorrhagic shock treatment.

Materials and Methods:

Twenty-two rats underwent a pressure-controlled hemorrhagic shock model and followed up for 24 hours. An infusion of apoptotic cells (Allocetra-OTS, Enlivex Therapeutics Ltd, Nes Ziona, Israel) was administered to the treatment group. Hemodynamics, blood counts, biochemistry findings, and cytokine profile were compared to a saline-resuscitated control group.

Results:

The treatment group’s mean arterial pressure decreased from 94.8 mmHg to 28.2 mmHg, resulting in an 8.13 mg/dL increase in lactate and a 1.9 g/L decrease in hemoglobin, similar to the control group. White blood cells and platelets decreased more profoundly in the treatment group. A similar cytokine profile after 24 hours was markedly attenuated in the treatment group 2 hours after bleeding. Levels of pro-inflammatory cytokines such as interleukin (IL)-1a (28.4 pg/mL vs. 179.1 pg/mL), IL-1b (47.4 pg/mL vs. 103.9 pg/mL), IL-6 (526.2 pg/mL vs. 3492 pg/mL), interferon γ (11.4 pg/mL vs. 427.9 pg/mL), and tumor necrosis factor α (19.0 pg/mL vs. 31.7 pg/mL) were profoundly lower in the treatment group.

Conclusion:

In a pressure-control hemorrhagic shock model in rats, apoptotic cell infusion showed preliminary signs of a uniform attenuated cytokine response. Apoptotic cell–based therapies might serve as a novel immunomodulatory therapy for hemorrhagic shock.

Frontiers in immunology2区 · 医学

Apoptotic Cells for Therapeutic Use in Cytokine Storm Associated With Sepsis– A Phase Ib Clinical Trial

2区 · 医学

ArticleOA

作者: Abutbul, Avraham ; El-Amore, Raja ; Reicher, Barak ; Falah, Batla ; van Heerden, Peter Vernon ; Zlotnick, Eitan ; Nama, Ahmad ; Mevorach, Dror ; Zimro, Sebastian ; Shabat, Yehudit ; Sviri, Sigal

Background:

Sepsis has no proven specific pharmacologic treatment and reported mortality ranges from 30%–45%. The primary aim of this phase IB study was to determine the safety profile of Allocetra™-OTS (early apoptotic cell) infusion in subjects presenting to the emergency room with sepsis. The secondary aims were to measure organ dysfunction, intensive care unit (ICU) and hospital stays, and mortality. Exploratory endpoints included measuring immune modulator agents to elucidate the mechanism of action.

Methods:

Ten patients presenting to the emergency room at the Hadassah Medical Center with sepsis were enrolled in this phase Ib clinical study. Enrolled patients were males and females aged 51–83 years, who had a Sequential Organ Failure Assessment (SOFA) score ≥2 above baseline and were septic due to presumed infection. Allocetra™-OTS was administered as a single dose (day +1) or in two doses of 140×106 cells/kg on (day +1 and +3), following initiation of standard-of-care (SOC) treatment for septic patients. Safety was evaluated by serious adverse events (SAEs) and adverse events (AEs). Organ dysfunction, ICU and hospital stays, and mortality, were compared to historical controls. Immune modulator agents were measured using Luminex® multiplex analysis.

Results:

All 10 patients had mild-to-moderate sepsis with SOFA scores ranging from 2–6 upon entering the study. No SAEs and no related AEs were reported. All 10 study subjects survived, while matched historical controls had a mortality rate of 27%. The study subjects exhibited rapid resolution of organ dysfunction and had significantly shorter ICU stays compared to matched historical controls (p<0.0001). All patients had both elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that gradually decreased following treatment.

Conclusion:

Administration of apoptotic cells to patients with mild-to-moderate sepsis was safe and had a significant immuno-modulating effect, leading to early resolution of the cytokine storm.

Clinical Trial Registration:

ClinicalTrials.gov Identifier: NCT03925857. (https://clinicaltrials.gov/ct2/show/study/NCT03925857).

Journal of hematology & oncology

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

Review

作者: Park, Chandler H ; Erick, Timothy K ; Joshi, Muskan ; Menon, Gayathri P ; Cappelli, Jared ; Sharma, Pushpa ; Wilkerson, William B ; Emmanuel, Nancy ; Leyfman, Yan

Abstract:

Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammation while stimulating hypoxia, and malignancy promotes hypoxia-induced cellular metabolic alterations leading to cell death, we propose a mechanistic interplay between both conditions that results in an upregulation of IL-6 secretion resulting in enhanced cytokine production and systemic injury. Hypoxia mediated by both conditions results in cell necrosis, dysregulation of oxidative phosphorylation, and mitochondrial dysfunction. This produces free radicals and cytokines that result in systemic inflammatory injury. Hypoxia also catalyzes the breakdown of COX-1 and 2 resulting in bronchoconstriction and pulmonary edema, which further exacerbates tissue hypoxia. Given this disease model, therapeutic options are currently being studied against severe SARS-COV-2. In this study, we review several promising therapies against severe disease supported by clinical trial evidence—including Allocetra, monoclonal antibodies (Tixagevimab–Cilgavimab), peginterferon lambda, Baricitinib, Remdesivir, Sarilumab, Tocilizumab, Anakinra, Bevacizumab, exosomes, and mesenchymal stem cells. Due to the virus’s rapid adaptive evolution and diverse symptomatic manifestation, the use of combination therapies offers a promising approach to decrease systemic injury. By investing in such targeted interventions, cases of severe SARS-CoV-2 should decrease along with its associated long-term sequelae and thereby allow cancer patients to resume their treatments.

117

项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的新闻（医药）

2026-04-30

·GlobeNewswire-Health Care

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange

The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today reported that its treasury asset, the RAIN token, has been listed on the HTX cryptocurrency exchange, effective April 29, 2026. The listing marks an important step forward for RAIN, significantly increasing its accessibility, global reach, and token liquidity. HTX (formerly Huobi) is a leading global cryptocurrency exchange serving over 160 countries and is one of the most recognized platforms in the industry. HTX consistently ranks among the top 10 digital assets exchanges worldwide on platforms like CoinMarketCap and CoinGecko, reflecting its strong liquidity, large user base, and highly active trading environment. In 2025, HTX's annual cumulative trading volume reached approximately $3.3 trillion across over 700 assets, and its user base grew to over 59 million in Q1 2026. “RAIN is the primary asset of Enlivex’s digital asset treasury. We view major exchange listings as meaningful milestones that may support liquidity and market access for our treasury holdings,” said Oren Hershkovitz, CEO of Enlivex. Enlivex’s digital asset treasury strategy is focused on the acquisition of RAIN tokens. Recently, the Company announced its total RAIN holdings had increased to approximately 78.8 billion tokens with a total value of $567 million (as of April 27, 2026). RAIN serves as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. The protocol enables users globally to create, trade, and resolve markets tied to real-world events through a transparent and automated on-chain framework About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, a leading decentralized prediction markets infrastructure. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Ltd.shachar@enlivex.com

免疫疗法

2026-04-28

·GlobeNewswire-Health Care

Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million

New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that as of April 27, 2026, Enlivex’s total RAIN holdings increased to 78,819,756,062 tokens, which had a total value of $567 million1. Oren Hershkovitz, Ph.D, CEO of Enlivex, said, “Securing additional RAIN at a material discount to recent market prices reflects our disciplined treasury strategy that we believe may potentially create additional shareholder value. Our approach is supported by what we are seeing in the broader industry: growing Institutional appetite for exposure to prediction markets.” Enlivex’s most recent acquisitions of RAIN tokens were made via partial exercises of the Company’s option to acquire up to 272,121,212,121 RAIN tokens from the Rain Foundation, which independently oversees the decentralized prediction markets Rain protocol, at a purchase price of $0.0033 per RAIN token. The option’s expiration date is Dec. 31, 2027. The option’s exercise price represents an approximately 55% discount to RAIN’s closing price on April 27, 2026. About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, a leading decentralized prediction markets infrastructure. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFOEnlivex Ltd.shachar@enlivex.com 1 Valuation is calculated using the closing price of the RAIN token as provided by https://coinmarketcap.com

并购免疫疗法

2026-04-23

·BioSpace

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

Nes-Ziona, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2026 World Congress on Osteoarthritis, taking place April 23-26, 2026, in West Palm Beach, Florida, USA. The presentations will feature 3-month and 6-month endpoints clinical data from the Phase IIa (NCT06233474) for Allocetra™ in patients with moderate-to-severe knee osteoarthritis (KOA). The Phase IIa data demonstrated clinically meaningful and statistically significant improvement of the Allocetra™-treated arm in reduction of pain and improvement of function, compared to the control placebo arm, in idiopathic age-related osteoarthritis patients (≥60 years), representing more than 50% of the total KOA market. The data will be presented by Prof. Philip Conaghan, Consultant Rheumatologist and Director of the NIHR Leeds Biomedical Research Centre. Professor Conaghan is an international leader in osteoarthritis and musculoskeletal imaging, who has authored more than 700 publications and chaired multiple global guidelines and trial initiatives. In addition, the Company will present comprehensive pharmacological characterization data supporting the novel immunomodulating mechanism of action of Allocetra TM . Oren Hershkovitz, Ph.D, CEO of Enlivex, commented "We are pleased that the OARSI 2026 team selected Enlivex to present this data at the 2026 World Congress on Osteoarthritis, which is the leading international congress on the topic of osteoarthritis. We look forward to presenting the depth of our clinical and pharmacological program for Allocetra™, including three-month and six-month efficacy and mechanistic characterization data behind our unique approach to addressing inflammatory, age-related joint disease." Poster Presentations: Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA TRIAL OF ALLOCETRA TM - AN INNOVATIVE INTRA-ARTICULAR APOPTOTIC CELL THERAPY IN KNEE OSTEOARTHRITIS DEMONSTRATES DURABLE EFFICACY AT 6 MONTHS (NCT06233474) Abstract ID: 4466183 Poster Number: 405 Date & Time: April 24 & 25 2026 | 03:30 PM – 04:15 PM ET Title: PHARMACOLOGICAL CHARACTERIZATION OF ALLOCETRA TM ; A NOVELMACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA ARTICULARTREATMENT IN OSTEOARTHRITIS Abstract ID: 4466242 Poster Number: 549 Date & Time: April 24 & 25 2026 | 03:30 PM – 04:15 PM ET About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN token, which is the token of the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com

临床2期临床结果细胞疗法免疫疗法

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床2期	以色列	Enlivex Ltd.	2024-01-26
局部晚期恶性实体瘤	临床2期	以色列	Enlivex Ltd.	2022-11-15
局部晚期恶性实体瘤	临床2期	西班牙	Enlivex Ltd.	2022-11-15
转移性肿瘤	临床2期	以色列	Enlivex Ltd.	2022-06-29
腹膜继发性恶性肿瘤	临床2期	以色列	Enlivex Ltd.	2022-06-29
急性呼吸窘迫综合征	临床2期	以色列	Enlivex Ltd.	2021-09-01
胆管炎	临床2期	比利时	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	法国	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	以色列	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	荷兰	Enlivex Ltd.	2020-11-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06233474 (ENX-CL-05-001 \| ENXCL05001, GlobeNewswire) 人工标引	临床2期	膝关节炎	-	Allocetra	網餘蓋廠網鑰醖鏇壓膚(膚遞範糧顧鏇襯鬱壓製) = 膚獵積壓壓膚夢壓醖廠鹹遞鹽蓋構鹽餘築餘製 (膚蓋憲積繭繭構鑰製蓋 ) 更多	积极	2025-11-24
				Placebo	網餘蓋廠網鑰醖鏇壓膚(膚遞範糧顧鏇襯鬱壓製) = 餘鏇遞壓簾衊築憲遞鹽鹹遞鹽蓋構鹽餘築餘製 (膚蓋憲積繭繭構鑰製蓋 ) 更多
NCT06233474 (ENXCL05001, GlobeNewswire)	临床1/2期	骨关节炎 \| 膝关节炎	130	AllocetraOTS	糧齋獵獵襯網構夢觸衊(範構鏇獵範築夢夢鹹鹹): Difference (%) = 26 更多	积极	2025-08-18
				placebo
EULAR2025	临床1/2期	膝关节炎	15	AllocetraTM	網觸壓繭艱窪選獵齋鑰(蓋餘窪餘構醖築簾獵蓋) = 壓襯鏇築夢齋鑰艱糧廠艱築鹽鑰築淵網齋鑰繭 (糧鹽繭鏇觸壓繭壓艱蓋, 35.1 ~ 69.7) 更多	积极	2025-06-11
NCT06233474 (GlobeNewswire) 人工标引	临床1/2期	膝关节炎	12	Allocetra	醖餘遞鏇築選夢醖鹹觸(餘襯鏇膚選窪築餘顧簾) = 夢簾簾糧獵鹹網鑰窪鏇網製觸餘夢廠構糧夢構 (顧齋窪襯範選窪顧繭窪 ) 更多	积极	2024-12-03
NCT06233474 (Biospace) 人工标引	临床1/2期	膝关节炎	9	Allocetra	願壓夢鹽蓋願糧鹹鏇簾(鹹廠構鑰艱夢餘願鬱鬱) = 衊壓願醖衊觸網蓋鹽廠夢繭繭遞遞艱願構範糧 (鏇艱觸壓觸醖窪積醖窪 ) 更多	积极	2024-06-17
NCT04612413 (GlobeNewswire) 人工标引	临床2期	脓毒症	-	Allocetra	襯襯鬱齋鑰淵衊鏇範淵(糧願廠繭範蓋餘壓醖淵) = 憲壓憲網淵蓋鹽襯淵醖築壓糧網襯蓋築艱蓋蓋 (範獵艱繭願膚鬱範鑰膚 ) 更多	积极	2024-04-11
NCT03925857 (P-SOFA-1, Pubmed \| Front Immunol) 人工标引	临床1期	脓毒症	10	Allocetra™-OTS	廠艱網鑰壓鬱壓憲願觸(醖衊醖製範夢鹽夢衊醖) = No SAEs were reported. 觸壓糧夢醖網構廠鹽窪 (廠鬱選鏇鏇齋襯網鑰鹹 ) 更多	积极	2021-09-30
				historical controls
NCT04590053 (GlobeNewswire) 人工标引	临床2期	新型冠状病毒感染	16	Allocetra	獵築簾艱範壓窪獵淵膚(簾構網鹽廠窪膚蓋選觸) = 鹹鹽襯膚觸鬱顧積願蓋夢窪鬱醖膚艱繭糧觸夢 (製選醖獵製鬱選築糧醖 ) 更多	积极	2021-02-03
NCT03925857 (P-SOFA-1, GlobeNewswire) 人工标引	临床1期	脓毒症	47	Allocetra	遞憲鏇夢選夢艱襯膚簾(淵鏇選遞廠廠網憲積醖) = 積餘餘遞壓願壓獵繭製構憲窪醖襯鹽鑰網廠網 (築觸憲繭製餘網壓廠齋 ) 更多	积极	2020-03-18
				Standard of Care	鬱艱壓壓廠襯築淵願製(糧構壓簾廠艱繭觸遞齋) = 網壓遞醖蓋鏇繭餘齋繭齋壓醖壓獵鏇製憲構襯 (獵齋顧積膚淵壓壓膚衊 ) 更多